Lamisil Dermgel 1% gel in 15g tube

The instruction for medical use of LAMIZIL DERMGEL medicine the Trade name Lamizil Dermgel the International non-proprietary name Terbinafin Lekarstvennaya a form Gel of 1% Structure of 1 g of gel contains active agent - terbinafin 10 mg excipients: benzyl alcohol, carbomer (free from benzene), isopropyl myristate, butyl hydroxytoluene, sorbitan laurate, polysorbate 20, sodium hydroxide, ethanol of 96%, water purified. The description Brilliant gel, from white till almost white color Pharmacotherapeutic group Other antifungal drugs for external use. Terbinafin. The ATX D01AE15 code the Pharmacological Pharmacokinetics At properties topical administration of a terbinafin absorption - less than 5%, has insignificant systemic action. Quickly gets through skin and collects in sebaceous glands. High concentrations are created in hair follicles and hair. After drawing on skin, the maximum concentration of drug is reached in 4 hours. When putting drug once a day within one week its maximum concentration (Smakh) in a corneal layer increases. After the 7 a day course of treatment drug is found during the next 7 days. A pharmacodynamics of Lamizil®Dermgel - the antifungal drug for topical administration possessing a wide range of activity. In small concentration has fungicide effect (causes death of a cell of a mushroom) concerning dermatophytes, mold and certain dimorphous mushrooms. The activity concerning barmy mushrooms, depending on their look, can be fungicidal or fungistatic (delays growth of a cell of a mushroom). Lamizil Dermgel in unusual way changes an early stage of the biosynthesis of sterols happening in mushrooms. It leads to deficiency of ergosterol and to intracellular accumulation of squalene that causes death of a cell of a mushroom. Action is carried out by inhibition of the enzyme of a skvalenepoksidaza located on a cellular membrane of a mushroom. Lamizil Dermgel has the anti-inflammatory, antipruritic, epithelizing effect. The gel Lamizila Dermgelya component has the cooling effect. Lamizil Dermgel does not influence the system of P450 cytochrome at the person and, respectively, metabolism of hormones or other medicines. Indications - prevention and treatment of fungal infections of skin, including mycoses of feet (foot fungus), an inguinal epidermophitia (tinea cruris), fungal infections of smooth skin of a body (tinea corporis) caused by such dermatophytes as Trichophyton (including, T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum), Microsporum canis and Epidermophyton floccosum - multi-colored deprive (Pityriasis versicolor), the caused Pityrosporum orbiculare (also known as Malassezia furfur). The route of administration and doses Is applied at adults of 1 times a day, within 1 week. Outwardly. Lamizil Dermgel apply on any of indications once a day. Before use of drug it is necessary to clean and dry affected areas carefully. Lamizil Dermgel slightly rub to sites as struck, and adjacent intact skin. In case of the infections which are followed by an intertrigo (under mammary glands, between fingers, in buttock and inguinal folds), the field of drawing dermgelya can be covered with a gauze, especially at night. Reduction of expressiveness of clinical manifestations is usually noted in the first days of treatment. In case of irregular treatment or its premature termination there is a risk of a recurrence of an infection. In case in a week of treatment signs of improvement are not noted, it is necessary to revise the diagnosis. Patients of advanced age Are not present the bases to assume that for elderly people it is required to change drug dosing or that they note the side effects differing from those at patients of younger age. How to handle drug Before the first use of drug it is necessary to puncture the sealing membrane by means of the edge fixed outside into the screwing-up cap. Side effects Often - reddening, peeling of skin on sites of application Infrequently - damages of skin, a scab, diseases of skin, pigmentation disturbance, reddening, burning sensation of skin - pain and irritation of skin in the field of putting drug Is rare - allergic reactions (generalized rash, a small tortoiseshell, a Quincke's disease, repeated allergic reaction) - irritation of eyes - xeroderma, contact dermatitis, eczema - hypersensitivity, Contraindication rash to use - hypersensitivity to a terbinafin or to any of the excipients which are a part of drug - pregnancy and the period of a lactation - children's age up to 18 years. Medicinal interactions Any medicinal interactions for Lamizil Dermgel are not described Special instructions It is necessary to be careful when drawing Lamizil Dermgel's on the damaged sites of skin as alcohol can cause irritation. Lamizil Dermgel is intended only for external use. Drug should not be put on a face. It is necessary to avoid hit it in eyes as it can cause irritation. At accidental hit of drug in eyes, they should be washed immediately with flowing water, and in case of development of the resistant phenomena of irritation it is necessary to consult with the doctor. In case in a week of treatment signs of improvement are not noted, it is necessary to verify the diagnosis. The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms does not affect ability, ability to run the vehicle or potentially dangerous mechanisms. Overdose Symptoms: at accidental intake the headache, dizziness, nausea, pain in epigastriums are observed. Treatment: activated carbon, if necessary - symptomatic maintenance therapy. A form of release and packing On 15 g of drug in tubas aluminum with the propylene screw-on covers supplied with ledges for perforation of a membrane. On 1 tuba together with the instruction for medical use in the state and Russian languages place in a pack from cardboard. To Store storage conditions at a temperature not above 30 °C. To store out of children's reach! The period of storage Drug should not be used 3 years after the term specified on packing. Prescription status Without prescription of Proizvoditel Novartis Konsyyumer Hels SA, Switzerland Novartis Consumer Health SA., Switzerland the Name and the country of the owner of the registration certificate of Novartis Konsyyumer Hels SA, Switzerland the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods) and responsible for post-registration observation of safety of medicine of KH KAZAKHSTAN GSC LLP Almaty, Manas St., 32A.